Effective Neutralizing Antibody Response Against SARS-CoV-2 Virus and Its Omicron BA.1 Variant in Fully Vaccinated Hematological Patients.

Autor: De Novellis D; Department of Medicine, Surgery, and Dentistry, University of Salerno, Baronissi, Italy.; Hematology and Transplant Center, University Hospital 'San Giovanni di Dio e Ruggi d'Aragona', Salerno, Italy., Folliero V; Department of Medicine, Surgery, and Dentistry, University of Salerno, Baronissi, Italy.; Microbiology and Virology, University Hospital 'San Giovanni di Dio e Ruggi d'Aragona', Salerno, Italy., Giudice V; Department of Medicine, Surgery, and Dentistry, University of Salerno, Baronissi, Italy.; Hematology and Transplant Center, University Hospital 'San Giovanni di Dio e Ruggi d'Aragona', Salerno, Italy., Pezzullo L; Hematology and Transplant Center, University Hospital 'San Giovanni di Dio e Ruggi d'Aragona', Salerno, Italy., Sanna G; Department of Biomedical Sciences, Microbiology and Virology Unit, University of Cagliari, Cittadella Universitaria, 09042, Monserrato, Italy., Fontana R; Hematology and Transplant Center, University Hospital 'San Giovanni di Dio e Ruggi d'Aragona', Salerno, Italy., Guariglia R; Hematology and Transplant Center, University Hospital 'San Giovanni di Dio e Ruggi d'Aragona', Salerno, Italy., Zannella C; Department of Experimental Medicine, University of Campania 'Luigi Vanvitelli', 80138, Naples, Italy., Mettivier L; Hematology and Transplant Center, University Hospital 'San Giovanni di Dio e Ruggi d'Aragona', Salerno, Italy., Ferrara I; Hematology and Transplant Center, University Hospital 'San Giovanni di Dio e Ruggi d'Aragona', Salerno, Italy., Boccia G; Department of Medicine, Surgery, and Dentistry, University of Salerno, Baronissi, Italy., Buonanno MT; Hematology and Transplant Center, University Hospital 'San Giovanni di Dio e Ruggi d'Aragona', Salerno, Italy., Martorelli MC; Hematology and Transplant Center, University Hospital 'San Giovanni di Dio e Ruggi d'Aragona', Salerno, Italy., Luponio S; Hematology and Transplant Center, University Hospital 'San Giovanni di Dio e Ruggi d'Aragona', Salerno, Italy., Crudele A; Department of Medicine, Surgery, and Dentistry, University of Salerno, Baronissi, Italy., Pagliano P; Department of Medicine, Surgery, and Dentistry, University of Salerno, Baronissi, Italy., Sessa AM; Hematology and Transplant Center, University Hospital 'San Giovanni di Dio e Ruggi d'Aragona', Salerno, Italy., Velino F; Hematology and Transplant Center, University Hospital 'San Giovanni di Dio e Ruggi d'Aragona', Salerno, Italy., Langella M; Hematology and Transplant Center, University Hospital 'San Giovanni di Dio e Ruggi d'Aragona', Salerno, Italy., Manzin A; Department of Biomedical Sciences, Microbiology and Virology Unit, University of Cagliari, Cittadella Universitaria, 09042, Monserrato, Italy., Galdiero M; Department of Experimental Medicine, University of Campania 'Luigi Vanvitelli', 80138, Naples, Italy., Selleri C; Department of Medicine, Surgery, and Dentistry, University of Salerno, Baronissi, Italy. cselleri@unisa.it.; Hematology and Transplant Center, University Hospital 'San Giovanni di Dio e Ruggi d'Aragona', Salerno, Italy. cselleri@unisa.it., Franci G; Department of Medicine, Surgery, and Dentistry, University of Salerno, Baronissi, Italy. gfranci@unisa.it.; Microbiology and Virology, University Hospital 'San Giovanni di Dio e Ruggi d'Aragona', Salerno, Italy. gfranci@unisa.it., Serio B; Department of Medicine, Surgery, and Dentistry, University of Salerno, Baronissi, Italy. bianca.serio@sangiovanniruggi.it.; Hematology and Transplant Center, University Hospital 'San Giovanni di Dio e Ruggi d'Aragona', Salerno, Italy. bianca.serio@sangiovanniruggi.it.
Jazyk: angličtina
Zdroj: Clinical and experimental medicine [Clin Exp Med] 2023 Dec; Vol. 23 (8), pp. 4943-4953. Date of Electronic Publication: 2023 Oct 28.
DOI: 10.1007/s10238-023-01223-w
Abstrakt: SARS-CoV-2 and its variants cause CoronaVIrus Disease 19 (COVID-19), a pandemic disease. Hematological malignancies increase susceptibility to severe COVID-19 due to immunosuppression. Anti-SARS-CoV-2 neutralizing antibodies protect against severe COVID-19. This retrospective real-life study aimed to evaluate seropositivity and neutralizing antibody rates against SARS-CoV-2 and its Omicron BA.1 variant in hematological patients. A total of 106 patients with different hematologic malignancies, who have mostly received three or more vaccine doses (73%), were included in this study. Serum was collected between May and June 2022. The primary endpoint was anti-SARS-CoV-2 antibody response against ancestral (wild type; wt) and Omicron BA.1 virus, defined as a neutralizing antibody titer ≥ 1:10. Adequate neutralizing antibody response was observed in 75 (71%) and 87 (82%) of patients for wt and Omicron BA.1 variants, respectively.However, patients with B-cell lymphoproliferative disorders and/or those treated with anti-CD20 monoclonal antibodies in the prior 12 months showed a lower seropositivity rate compared to other patients against both Omicron BA.1 variant (73% vs 91%; P = 0.02) and wt virus (64% vs 78%; P = 0.16). Our real-life experience confirmed that full vaccination against SARS-CoV-2 induces adequate neutralizing antibody protection for both the wt virus and Omicron BA.1 variants, even in hematological frail patients. However, protective measures should be maintained in hematological patients, especially those with B-cell lymphoproliferative diseases treated with anti-CD20 monoclonal antibodies, because these subjects could have a reduced neutralizing antibody production.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: